NCT03391440 - A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease | Biotech Hunter

Enrollment

469

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Pelvic Inflammatory Disease

Interventions

DRUG

morinidazole

morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan